Lloyd KE, Hall LH, King N, et al. - Findings revealed a moderate to high probability that eligible users of aspirin would take part in a trial assessing the use of aspirin for preventive therapy. High day-to-day adherence was noted in participants in a trial.

• This systematic review was conducted to generate data about attitudes and behavior towards the use of aspirin for cancer prevention, and healthcare providers' attitudes towards implementing aspirin in practice.

• Overall 12 databases (e.g. MEDLINE, EMBASE) were explored to identify 38 studies (uptake and adherence data were all from trials and trials included healthy participants, those at higher risk of cancer, and those with cancer).

• Four studies documented moderate to high (40.9–77.7%) uptake to an aspirin trial in individuals who were eligible.

• High day-to-day adherence (≥80%) was revealed in the majority of the trials (18/22), and no link was found between gender and adherence in three trials.

• In three studies, moderate to high (43.6–76.0%) hypothetical willingness to use aspirin was noted.

• Aspirin was considered a suitable cancer prevention choice by a high proportion of healthcare providers (72.0–76.0%) in two studies.

• No qualitative studies were found.